Results 11 to 20 of about 2,269,258 (384)

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma [PDF]

New England Journal of Medicine, 2017
S. Neelapu, F. Locke, N. Bartlett, L. Lekakis, D. Miklos, C. Jacobson, I. Braunschweig, O. Oluwole, T. Siddiqi, Yi Lin, J. Timmerman, P. Stiff, J. Friedberg, I. Flinn, A. Goy, B. Hill, Mitchell R. Smith, A. Deol, U. Farooq, P. Mcsweeney, J. Muñoz, I. Avivi, J. Castro, J. Westin, J. Chavez, A. Ghobadi, K. Komanduri, R. Levy, E. Jacobsen, T. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Yi-zhou Jiang, J. Aycock, M. Elias, David D. Chang, J. Wiezorek, W. Go   +39 more
semanticscholar   +3 more sources

Advances in understanding of angioimmunoblastic T-cell lymphoma

Leukemia, 2020
It has been nearly half a century since angioimmunoblastic T-cell lymphoma (AITL) was characterized in the early 1970’s. Our understanding of the disease has dramatically changed due to multiple discoveries and insights.
S. Chiba, M. Sakata-Yanagimoto
semanticscholar   +1 more source

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

EJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li   +7 more
doaj   +1 more source

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Nature Communications, 2020
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX
D. Phillips, M. Matusiak, B. Gutierrez, S. Bhate, G. Barlow, Sizun Jiang, J. Demeter, K. Smythe, R. Pierce, S. Fling, N. Ramchurren, M. Cheever, Y. Goltsev, Robert West, M. Khodadoust, Youn H. Kim, C. Schürch, Garry P. Nolan   +17 more
semanticscholar   +1 more source

Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas [PDF]

Journal of Pathology and Translational Medicine, 2016
Background: Recent studies have revealed that the splicing factor neuro-oncological ventral antigen 1 (NOVA1) is enriched in fibroblasts and accumulated T cells of tertiary lymphoid structures.
Eun Kyung Kim, Sun Och Yoon, Soo Hee Kim, Woo Ick Yang, Yoon Ah Cho, Soo Jeong Kim   +5 more
doaj   +1 more source

Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. [PDF]

, 2017
Primary cutaneous CD8-positive aggressive epidermotropic T-cell lymphoma is a rare and poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the latest 2016 World Health Organization Classification of Cutaneous ...
Duvic, Madeleine, Girardi, Michael, Guitart, Joan, Ivan, Doina S, Junkins-Hopkins, Jacqueline, Kim, Ellen, Kim, Jinah, Kim, Youn H, Martinez-Escala, M Estela, Olsen, Elise A, Pincus, Laura B, Pulitzer, Melissa P, Rook, Alain H, Sable, Kimberly A, Samimi, Sara S, Selim, M Angelica, Subtil, Antonio, Tetzlaff, Michael T, Virmani, Pooja, Wood, Gary S   +19 more
core   +1 more source

A preclinical model for the ATLL lymphoma subtype with insights into the role of microenvironment in HTLV-1-mediated lymphomagenesis [PDF]

, 2018
\uef7f View references (83) Adult T cell Leukemia/Lymphoma (ATLL) is a mature T cell malignancy associated with Human T cell Leukemia Virus type 1 (HTLV-1) infection.
Adriana Mattiolo, Alberto Amadori, Alberto Amadori, Barbara Montini, Ilaria Cavallari, Luigi Chieco-Bianchi, Maria Assunta Piano, Maria Luisa Calabrò, Mattia Vicario   +8 more
core   +2 more sources

Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Clinical Epigenetics, 2020
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically aggressive diseases associated with poor prognosis. Except for ALK + anaplastic large-cell lymphoma (ALCL), most peripheral T-cell lymphomas are highly malignant and have ...
Ping Zhang, Mingzhi Zhang
semanticscholar   +1 more source

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

Haematologica, 2013
Clinical trials of immunotherapy in mantle cell lymphoma have not yet delivered desirable results, partly because of the inhibitory machinery of the tumor and its microenvironment.
Lijuan Wang, Jianfei Qian, Yong Lu, Haiyan Li, Hanying Bao, Donghua He, Zhiqiang Liu, Yuhuan Zheng, Jin He, Yi Li, Sattva Neelapu, Jing Yang, Larry W. Kwak, Qing Yi, Zhen Cai   +14 more
doaj   +1 more source

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy P. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source